Ironwood Pharma (IRWD) Misses Q1 EPS by 22c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- US stock futures rise as investors assess Democrats' midterm sweep
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts IRWD Hot Sheet
Join SI Premium – FREE
Ironwood Pharma (NASDAQ: IRWD) reported Q1 EPS of ($0.02), $0.22 worse than the analyst estimate of $0.20. Revenue for the quarter came in at $47.87 million versus the consensus estimate of $105.7 million.
GUIDANCE:
Ironwood Pharma sees FY2024 revenue of $405-425 million, versus the consensus of $447.8 million.
For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Uber (UBER) Tops Q3 EPS by 2c, Beats on Revenue; Offers Guidance
- Reservoir Media, Inc. (RSVR) Tops Q2 EPS by 2c; offers guidance
- Camtek Ltd (CAMT) Reports In-Line Q3 EPS, Beats on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
